SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
The association between cost sharing, prior authorization, and specialty drug utilization: A systematic review
11 references·0 citing·43 second hop
The association between cost sharing, prior authorization, and specialty drug utilization: A systematic review (2023)The association between cost sharing, pri…Trends in Prescription Drug Launch Prices, 2008-2021 (2022)Trends in Prescription Drug L…Many Medicare Beneficiaries Do Not Fill High-Price Specialty Drug Prescriptions (2022)Many Medicare Beneficiaries D…Refocusing Medication Prior Authorization on Its Intended Purpose (2020)Refocusing Medication Prior A…Association of Patient Out-of-Pocket Costs With Prescription Abandonment and Delay in Fills of Novel Oral Anticancer Agents (2017)Association of Patient Out-of…The Impact Of Specialty Pharmaceuticals As Drivers Of Health Care Costs (2014)The Impact Of Specialty Pharm…Out-of-Pocket Costs and Oral Cancer Medication Discontinuation in the Elderly (2014)Out-of-Pocket Costs and Oral …Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia (2013)Cost Sharing and Adherence to…Patient and Plan Characteristics Affecting Abandonment of Oral Oncolytic Prescriptions (2011)Patient and Plan Characterist…Cost Sharing, Family Health Care Burden, and the Use of Specialty Drugs for Rheumatoid Arthritis (2010)Cost Sharing, Family Health C…The Value of Specialty Oncology Drugs (2009)The Value of Specialty Oncolo…Association of Prescription Abandonment with Cost Share for High-Cost Specialty Pharmacy Medications (2009)Association of Prescription A…The Role of Cost-effectiveness Analysis in Health and Medicine (1996)The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine (1996)What Is the Price of Life and Why Doesn't It Increase at the Rate of Inflation? (2003)Public R&D Investments and Private-sector Patenting: Evidence from NIH Funding Rules (2018)Bilişsel Ekonomi: İktisatta Zihinsel Dönüşüm (2025)Zaman Tercihleri, Borçlanma ve Tasarruf Kararlarına Davranışsal Mikro İktisadi Bir Bakış (2025)The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's Experience (2013)National trends in prescription drug expenditures and projections for 2014 (2014)The 340B Drug Discount Program: Hospitals Generate Profits By Expanding To Reach More Affluent Communities (2014)Mind the Gap: Why Closing the Doughnut Hole Is Insufficient for Increasing Medicare Beneficiary Access to Oral Chemotherapy (2015)Why Are Biosimilars Not Living up to Their Promise in the US? (2019)Pharmacy Benefit Managers (2023)Celebrating the New (2008)Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study (2015)Financial toxicity and implications for cancer care in the era of molecular and immune therapies (2018)Financial Toxicity in Adults With Cancer: Adverse Outcomes and Noncompliance (2018)The Patient Protection and Affordable Care Act (2018)Benefit Design And Specialty Drug Use (2006)Income, Poverty, and Health Insurance Coverage In The United States: 2006 (2007)Out-of-pocket costs are on the rise for commonly prescribed neurologic medications (2019)Patient-reported financial toxicity in multiple sclerosis: Predictors and association with care non-adherence (2020)Pharmacy Benefits and the Use of Drugs by the Chronically Ill (2004)Prescription drug cost sharing: associations with medication and medical utilization and spending and health. (2007)The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts (2013)Population-Based Assessment of Cancer Survivors' Financial Burden and Quality of Life: A Prospective Cohort Study (2015)The high price of anticancer drugs: origins, implications, barriers, solutions (2017)Financial Burdens of Cancer Treatment: A Systematic Review of Risk Factors and Outcomes (2019)Deaths: preliminary data for 2003. (2005)Cost‐related medication nonadherence among adolescent and young adult cancer survivors (2017)Costs of cancer along the care continuum: What we can expect based on recent literature (2018)Financial Toxicity in Advanced and Metastatic Cancer: Overburdened and Underprepared (2019)Measuring financial toxicity as a clinically relevant patient‐reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST) (2016)Addressing Financial Barriers to Patient Participation in Clinical Trials: ASCO Policy Statement (2018)Understanding Financial Hardship Among Cancer Survivors in the United States: Strategies for Prevention and Mitigation (2019)Financial Toxicity in Cancer Care: Implications for Clinical Care and Potential Practice Solutions (2023)The Medicare Payment Advisory Commission. (1998)Health Care Spending in the United States and Other High-Income Countries (2018)Administrative Burden and Costs of Prior Authorizations in a Dermatology Department (2020)The High Cost of Prescription Drugs in the United States (2016)Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018 (2020)High drug prices are not justified by industry’s spending on research and development (2023)Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000–20: a retrospective analysis (2024)Chronic Disease Prevalence in the US: Sociodemographic and Geographic Variations by Zip Code Tabulation Area (2024)
this work references cited by second hop

References

  • 2013Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia500 cited
  • 2011Patient and Plan Characteristics Affecting Abandonment of Oral Oncolytic Prescriptions249 cited
  • 2017Association of Patient Out-of-Pocket Costs With Prescription Abandonment and Delay in Fills of Novel Oral Anticancer Agents155 cited
  • 2022Trends in Prescription Drug Launch Prices, 2008-2021111 cited
  • 2014Out-of-Pocket Costs and Oral Cancer Medication Discontinuation in the Elderly103 cited
  • 2009Association of Prescription Abandonment with Cost Share for High-Cost Specialty Pharmacy Medications85 cited
  • 2022Many Medicare Beneficiaries Do Not Fill High-Price Specialty Drug Prescriptions82 cited
  • 2020Refocusing Medication Prior Authorization on Its Intended Purpose65 cited
  • 2014The Impact Of Specialty Pharmaceuticals As Drivers Of Health Care Costs62 cited
  • 2009The Value of Specialty Oncology Drugs60 cited
  • 2010Cost Sharing, Family Health Care Burden, and the Use of Specialty Drugs for Rheumatoid Arthritis52 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work